Tuberc Respir Dis > Volume 34(4); 1987 > Article
Tuberculosis and Respiratory Diseases 1987;34(4):308-313.
DOI: https://doi.org/10.4046/trd.1987.34.4.308    Published online December 1, 1987.
The Effect of Ipratropium Bromide as A Bronchodilator in Chronic Obstructive Pulmonary Disease
Kye Young Lee, Young Whan Kim, Sung Koo Han, Young Soo Shim, Keun Youl Kim, Yong Choi Han
Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea
만성폐색성폐질환에서 Ipratropium Bromide의 기관지확장효과에 관한 연구
이계영, 김영환, 한성구, 심영수, 김건열, 한용철
Abstract
Ipratropium bromide is a new inhaled bronchodilator with anticholinergic properties. The effect of this compound (40 ug) was compared to Fenoterol (400 ug) with beta-adrenergic properties and to combination of 2 drugs in 14 patients with COPD. The drugs were administered by metered dose inhaler, after which FFV 1.0 was checked at time interval of 15 min, 30 min, 60 min, and 90 min. We investigated the bronchodilating effect (FEV1/ Baseline FEV1 ) and side effects of each cases and the results were summarized as followings; 1) The bronchodilating effect with the aerosol of Fenoterol was the increment of 11.1± 7.6% in 15 min, 14.2± 6.0% in 30 min, 15.4± 8.6% in 60 min, and 15.1±10.8%in 90 min and showed the maximal effect at the time of 60 minute. In contrast, the bronchodilating effect with the aerosol of Ipratropium bromide was the increment of 13.4± 7.6% in 15 min 19.4± 11.3% in 30 min, 20.6± 10.1 % in 60 min, and 22.9 ± 9.6% in 90 min and showed the maximal effect at the time of 90 min. 2) The bronchodilating effect of Ipratorpium bromide was more pronounced than that of Fenoterol (p < 0.05). 3) The bronchodilating effect in the combination of two drugs, was., the increment of 16.9± 11.0% in 15min, 21.3±11.1% in 30min, 24.3±13.4% in 60min, and 29.7±12.8% in 90min and showed the maximal effect at the time of 90 min. There was the incremental tendency of the bronchodilating effect as the time-course and the additive effects of 2 drugs was observed. 4) The side effects of inhaled Ipratropium bromid were nausea, dry mouth, and throat irritation but not the degree to discontinue the medication. 5) We concluded that Ipratropium bromide is an effective and safe bronchodilator in patients with COPD and its bronchodilating effect is appeared to be slower but more potent than Fenoterol.


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2022 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next